Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Altimmune, Inc. (ALT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.37-0.98 (-7.34%)
At close: 04:00PM EDT
12.25 -0.12 (-0.97%)
After hours: 07:56PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.35
Open12.95
Bid12.20 x 800
Ask12.50 x 1400
Day's Range11.70 - 12.97
52 Week Range3.83 - 23.49
Volume2,701,573
Avg. Volume2,571,555
Market Cap491.566M
Beta (5Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)-1.91
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 20, 2017
1y Target Est23.14
  • GlobeNewswire

    Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

    All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions in liver fat, with a 68.5% relative reduction in liver fat content in subjects receiving 1.8 mg dose at 12 weeks of treatmentMean weight loss of 4.9% (placebo-adjusted 4.7%) in subjects without diabetes receiving 1.8 mg dose at 12 weeks of treatmentAltimmune to host conference call today at 8:30 am ET GAITHERSBURG, Md., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nas

  • GlobeNewswire

    Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update

    Topline data from 12-week Phase 1b trial in subjects with obesity/overweight and non-alcoholic fatty liver disease (NAFLD) expected mid-September 2022GAITHERSBURG, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2022, and provided a business update. “We continue to advance the development of pemvidutide, our GLP-1/glucagon dual receptor agonist, and look

  • GlobeNewswire

    Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11

    GAITHERSBURG, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on August 11 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https

Advertisement
Advertisement